FRANCES TURREGANO: Open Payments
NPI 1144297763 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$368 in 21 payments from 12 companies in 2025. Trend: 2023 $1,444 · 2024 $930 · 2025 $368
Food & beverage: $368
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $67 |
| ABBVIE INC. | 4 | $63 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| Corcept Therapeutics | 2 | $32 |
| PFIZER INC. | 1 | $28 |
| Averitas Pharma Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $18 |
| Exact Sciences Corporation | 1 | $16 |
Products named: TRELEGY ELLIPTA, Korlym, Ozempic, ZAVZPRET, FARXIGA, QUTENZA, Wegovy, GVOKE HYPOPEN.
Industry payments across LA — which companies pay providers there.
